scholarly journals PMH5 A DIRECT MEDICAL COST ANALYSIS OF GEROPSYCHIATRIC PATIENTS IN TAIWAN

2010 ◽  
Vol 13 (7) ◽  
pp. A553
Author(s):  
CM Liu ◽  
CS Li ◽  
CC Liu
Keyword(s):  
Cost Analysis ◽  
Direct Medical Cost ◽  
Medical Cost

scholarly journals PMS22 Direct Medical Cost of Osteoporosis in Saudi Arabia: A Single-Center Retrospective Cost Analysis

2020 ◽  
Vol 23 ◽  
pp. S596
Author(s):  
B. Balkhi ◽  
S. Alqusair ◽  
B. Alotaibi ◽  
A. Alghamdi ◽  
Y. AlRuthia ◽  
...  
Keyword(s):  
Saudi Arabia ◽  
Cost Analysis ◽  
Direct Medical Cost ◽  
Medical Cost ◽  
Single Center

scholarly journals Direct Medical Cost Analysis Among Coronary Heart Disease and Heart Failure Outpatients at One Hospital

2019 ◽  
Vol 9 (2) ◽  
Author(s):  
Nunik Dewi Kumalasari ◽  
Abdul Rahem ◽  
Bobby Presley ◽  
Eko Setiawan
Keyword(s):  
Heart Failure ◽  
Coronary Heart Disease ◽  
Heart Disease ◽  
Cost Analysis ◽  
Direct Medical Cost ◽  
Medical Cost ◽  
Interprofessional Collaboration ◽  
Budget Allocation ◽  
Public Hospitals ◽  
Long Term Treatment

Long-term treatment of cardiovascular disease may give impact in a high burden of medical cost for the patient. A concern arises whether the health budget allocation prepared by the Indonesian Government through "Jaminan Kesehatan Nasional" program is enough to cover medical cost for the outpatient treatment. This study aims to calculate the direct medical cost of patients with coronary heart disease and heart failure and compare it with the Indonesian Case Base Groups (INA-CBGs) tariff. This is a prospective and observational study carried out in one of the public hospitals in East Java between February and April 2015. All data related to outpatients with coronary heart disease and heart failure were analysed. Direct medical cost analysis in this study calculated from a combination of cost of medication, health professional services, electrocardiography, emergency care services, and laboratory test component, then it was compared with INA-CBGs tariff from ICD 10. Total of 390 patients included were 387 patients with coronary heart disease (99.23%) and three (3) patients with heart failure (0.77%). Average direct medical cost for patients with coronary heart disease and heart failure were IDR 130.593,6 (range IDR 50.282 – IDR 385.911) and IDR 128.587 (range IDR 112.832 – IDR 140.103), respectively. Even though this study showed that budget allocation of INA-CBGs could cover the average direct medical cost of patients with both of diseases, some patients had a direct medical cost higher than the limit of INA-CBGs allocation. Therefore, an optimal interprofessional collaboration between physician and pharmacist needed to provide medical treatment based on patient needs and keep it within budget allocation range.

scholarly journals Direct Medical Cost Analysis of Indian COVID-19 Patients Requiring Critical Care Admission

2021 ◽  
Vol 25 (10) ◽  
pp. 1118-1123
Author(s):  
Shivakumar Iyer ◽  
Kamini N Reddy ◽  
Jignesh Shah ◽  
Monidipa Chowdhury ◽  
Naveen Yerrapalem ◽  
...  
Keyword(s):  
Critical Care ◽  
Cost Analysis ◽  
Direct Medical Cost ◽  
Medical Cost ◽  
Critical Care Admission

scholarly journals EVALUATION OF PHARMACOECONOMIC DIRECT COST IN DIABETES PATIENTS

2017 ◽  
Vol 10 (4) ◽  
pp. 38
Author(s):  
Venkateswarlu Konuru ◽  
Kamala Sangam ◽  
Anifa Mohammed ◽  
Swathi Kanneganti
Keyword(s):  
Health Care ◽  
Diabetic Patient ◽  
Direct Medical Cost ◽  
Medical Cost ◽  
Average Cost ◽  
Health Care Cost ◽  
Vascular Complications ◽  
Illness Study ◽  
Total Average Cost ◽  
Total Average

Objective:  Diabetes Mellitus (DM) is a major cause of disability, morbidity and mortality Worldwide. The objective of this study is to evaluate the Pharmacoeconomic direct health care cost in type II Diabetes with complications and Diabetes alone: A cost of illness study. Methods:  A Prospective observational study was conducted for one year at the Care diabetes Center; Warangal. The enrolled patients were followed and the information collected contains: total direct costs, which include direct medical costs and direct nonmedical cost. The data observed was analyzed for the average cost incurred in treating the diabetic patient. Results:  The total average costs per diabetic patient without complications was Rs. 8695.7±1341,  this includes the average direct medical cost Rs. 6366.50± 561.12, the average lab cost Rs. 1368.84±64.8, the average direct non Medical Cost was Rs. 960.36±14.04 compared to  those with DM complications,the total average cost was Rs. 12960.73±549.96 for macro vascular complications, Rs. 11039.11±265.36 for micro vascular complications. To treat Diabetes with comorbidities which include both micro and macro complications the total average cost was  Rs. 16658.13±1393.44, the average direct medical cost was Rs. 14071.77±2884.68, the average lab cost Rs. 1628.04±51, the average direct non Medical Cost was Rs.958.32±13.08. The costs were found to increase progressively with the increase in the number of complications. Costs also differed significantly across the types of complications. Conclusion: Our study concludes that the cost of Diabetes with complications resulted about 2 times higher than compared to Diabetes alone.Key words:  Cost analysis; diabetes; economics; health care; direct medical cost; non medical cost

scholarly journals Direct medical cost of radiation therapy for cancer patients in Taiwan

Health ◽  
2013 ◽  
Vol 05 (06) ◽  
pp. 989-993
Author(s):  
Henry W. C. Leung ◽  
Agnes L. F. Chan
Keyword(s):  
Radiation Therapy ◽  
Direct Medical Cost ◽  
Cancer Patients ◽  
Medical Cost

scholarly journals Economic Burden of Tuberculosis Diabetes Co-Morbidity in Tuberculosis Patients Attending Two Chest Clinics in Lagos State

2021 ◽  
Vol 16 (2) ◽  
pp. 91-100
Author(s):  
F.A. Ayeni ◽  
O.O. Oyetunde ◽  
B.A. Aina ◽  
H.O. Yarah
Keyword(s):  
Direct Medical Cost ◽  
Medical Cost ◽  
Indirect Costs ◽  
Medical Costs ◽  
Female Patients ◽  
Direct Medical Costs ◽  
Tb Treatment ◽  
Co Morbidity ◽  
Lagos State ◽  
Significant Burden

Background: Diabetes mellitus (DM) increases the risk of developing tuberculosis (TB) three-fold. The cost of accessing care for TB-DM co-morbidity poses a significant burden on patients, as they bear both direct and indirect costs of treatment, mostly of out-of-pocket.Objective: To estimate the direct medical cost of illness in patients with TB-DM co-morbidity in two chest clinics in Lagos State.Materials and Methods: An observational study, carried out in two chest clinics in Lagos State to evaluate direct medical costs associated with TBDM co-morbidity during TB treatment. A semi structured questionnaire, pharmacy price list of drugs and an online transportation service lara.ng was employed to document and quantify prescribed medications, laboratory investigations, number of clinic attendance and attendant transportation costs.Results: Among the participants, 53.8% were females. The mean age was 50.7±9.7 years. The total direct medical and non-medical costs for TBDM management was NGN8,604,819 (USD24,585.20) for the duration of TB treatment. Average cost per patient (CPP) was NGN179,384.85 (USD512.53). This was equivalent to 49.8% of the current national minimum wage. Male patients incurred more mean direct medical cost than female patients (NGN26, 647.90 vs NGN24, 020.40), while female patients incurred more mean direct non-medical costs than the males (NGN22, 314.30 versus NGN13, 041.70). Patients aged 60 years and above incurred the highest mean direct costs compared to other age groups.Conclusion: Direct medical costs are substantial in TBDM co-morbidity and increase with age.

The health and economic burden of chickenpox and herpes zoster in Belgium

2012 ◽  
Vol 140 (11) ◽  
pp. 2096-2109 ◽  
Author(s):  
J. BILCKE ◽  
B. OGUNJIMI ◽  
C. MARAIS ◽  
F. DE SMET ◽  
M. CALLENS ◽  
...  
Keyword(s):  
Herpes Zoster ◽  
General Practitioner ◽  
Direct Medical Cost ◽  
Medical Cost ◽  
Quality Adjusted Life Years ◽  
Varicella Zoster ◽  
Hospitalization Rates ◽  
Life Years ◽  
Life Years Lost ◽  
Quality Adjusted Life

SUMMARYVaricella-zoster virus causes chickenpox (CP) and after reactivation herpes zoster (HZ). Vaccines are available against both diseases warranting an assessment of the pre-vaccination burden of disease. We collected data from relevant Belgian databases and performed five surveys of CP and HZ patients. The rates at which a general practitioner is visited at least once for CP and HZ are 346 and 378/100 000 person-years, respectively. The average CP and HZ hospitalization rates are 5·3 and 14·2/100 000 person-years respectively. The direct medical cost for HZ is about twice as large as the direct medical cost for CP. The quality-adjusted life years lost for ambulatory CP patients consulting a physician is more than double that of those not consulting a physician (0·010vs. 0·004). In conclusion, both diseases cause a substantial burden in Belgium.

Sign in / Sign up

Export Citation Format

Share Document